The principal aim of this study was to optimise the diagnosis of canine neuroangiostrongyliasis (NA). Ninety-two cases were seen between 2010 and 2020. Dogs were aged from 7 weeks to 14 years (median 5 months), with 73/90 (81%) less than 6 months and 1.7 times as many males as females. The disease became more common over the study period. Most cases (86%) were seen between March and July. CSF was obtained from the cisterna magna in 77 dogs, the lumbar cistern in five, and both sites in three. Nucleated cell counts for 84 specimens ranged from 1 to 146,150 cells/μL (median 4,500). Percentage eosinophils varied from 0 to 98% (median 83%). When both cisternal and lumbar CSF were collected, inflammation was more severe caudally. Seventy-three CSF specimens were subjected to ELISA testing for antibodies against A. cantonensis; 61 (84%) tested positive, titres ranging from <100 to ≥12,800 (median 1,600). Sixty-one CSF specimens were subjected to qPCR testing using a new protocol targeting a bioinformatically-informed repetitive genetic target; 53/61 samples (87%) tested positive, CT values ranging from 23.4 to 39.5 (median 30.0). For 57 dogs, it was possible to compare CSF ELISA serology and qPCR. ELISA and qPCR were both positive in 40 dogs, in five dogs the ELISA was positive while the qPCR was negative, in nine dogs the qPCR was positive but the ELISA was negative, while in three dogs both the ELISA and qPCR were negative. NA is an emerging infectious disease of dogs in Sydney, Australia.